secwatch.observer — SEC 8-K summary
======================================

Issuer:     GENELUX Corp (GNLX)
CIK:        0001231457
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0001493152-23-022627
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genelux provides Phase 3 enrollment timeline for Olvi-Vec and cash runway into Q1 2026
--------------------------------------------------------------------------------

- Enrollment for Phase 3 trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer expected to complete mid-2024 with 11-month follow-up.
- Initial interim data for Phase 2 trial of Olvi-Vec in recurrent non-small-cell lung cancer expected as early as mid-2024.
- Cash operating runway expected to extend into first quarter of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1231457/000149315223022627/0001493152-23-022627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1231457/000149315223022627/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-022627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer